Severe vulvovaginal candidiasis(VVC)
Conditions
Interventions
Experimental group:Ketoconazole suppository, 1 capsule per night for 6 days
Control group:Miconazole nitrate vaginal soft capsule, 1 capsule per night for 6 days
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Patients with severe VVC whose symptom and sign scores >=7; 2. Women aged 18-50 years, married or have a sexual history and are not menstruating; 3. Women of reproductive age agreed to use barrier contraception during the study period; 4. Volunteer and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant and lactating patients; 2. Allergic to the pharmaceutical ingredients used in the research; 3. Patients with trichomoniasis vaginitis and bacterial vaginosis; 4. Patients who have used systemic antifungal drugs in the last three months and vulvovaginal antifungal drugs in the last two weeks; 5. Those who have received treatment for other vulvovaginal diseases or had vaginal lavage in the past two weeks; 6. Suspected cervical malignant lesions; 7. Systemic use of glucocorticoid or immunosuppressant within three months; 8. Participated in other drug clinical researchers within three months; 9. Other reasons cited by the researchers for not being included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total clinical effective rate (improvement rate of symptom and sign score >=67% and mycological test negative) ; | — |
Countries
China
Contacts
Public ContactZhang Dai
Peking University First Hospital
Outcome results
None listed